Prognostic value of integrating CT morphological features and PET volumetric metabolic parameters in surgically resected stage IA non-small cell lung cancer: a two-center retrospective study Authors: Jingjie Shang, Xiaobei Duan, Yingjun He, Biao Wu, Qijun Cai, Xiaoling Cao, Yongjin Tang, Jinci Mai, Simin Tan, Huihu Li, Xueying Ling, Binhao Huang, Hao Xu Published: 2025 ABSTRACT BackgroundBoth ground-glass opacity (GGO) components on computed tomography (CT) and metabolic information derived from positron emission tomography (PET) are associated with prognosis in early‑stage non-small cell lung cancer (NSCLC) patients. The purpose of this study was to evaluate whether their combined assessment could improve risk stratification in surgically resected stage IA NSCLC.MethodsWe retrospectively analyzed 212 consecutive patients with stage IA NSCLC from two medical centers who underwent 18F-FDG PET/CT before curative surgery between November 2012 and October 2024. The cohort was divided into feasibility evaluation (n = 152) and external validation (n = 60) groups. Primary tumor maximum standardized uptake values (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured. Optimal PET parameter cutoffs for progression-free survival (PFS) were determined using receiver operating characteristic curve analysis in the feasibility cohort. A two-point prognostic scoring system combining GGO features and the multivariable-identified prognostic PET parameters was developed and validated in both cohorts using log-rank tests.ResultsFor the feasibility cohort, the optimal cut-off values for the prediction of PFS were 6.2, 1.9 mL, and 11.7 for SUVmax, MTV, and TLG, respectively. Both patients with primary tumors exceeding these metabolic parameters and those in the GGO-negative subgroup showed significantly shorter PFS (all P < 0.05). Multivariable analysis identified GGO [hazard ratio (HR) = 8.137; 95% CI: 1.035–63.998; P = 0.046] and TLG (HR = 4.993; 95% CI: 1.831–13.612; P = 0.002) as independent prognostic factors, even after adjusting for histopathology and other PET parameters. The two-point prognostic scoring system, which consisted of GGO and TLG, stratified patients into low-, moderate-, and high-risk groups. In the feasibility cohort, PFS demonstrated statistically significant differences between the three groups (all P < 0.05), with similar trends in the external validation cohort.ConclusionsThe two-point prognostic scoring system, combining morphological GGO features with volumetric metabolic parameters TLG, provided a simple yet effective method for enhancing prognostic stratification in patients with surgically resected stage IA NSCLC.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40644-025-00954-1. Background Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Curative surgical resection is currently the standard of treatment for early-stage NSCLC [1]. However, despite successful surgical resection, tumor recurrence is observed in 8.8–29.8% of patients with stage IA NSCLC [2–4], and the 5-year survival rate following recurrence is exceedingly low, ranging from 15.0% to 16.6% [4]. Although adjuvant systemic therapy has been shown to reduce recurrence rates, it is not routinely recommended due to lack of significant survival benefit in unselected patients and potential treatment toxicities [5, 6]. Thus, identification of the subset of patients at the highest risk for recurrence who have the greatest need for additional systemic therapy is needed. Previous studies have shown that early-stage NSCLC with ground-glass opacity (GGO) component has a better prognosis than those with solid nodules of equivalent consolidation size [7–10]. Hattori et al. [7], demonstrated that maximum tumor size has prognostic value in patients with early-stage NSCLC only when lung tumors without the GGO component. In other words, this implies that the presence of GGO appears to be of greater prognostic importance, overshadowing the impact of solid component size in early-stage NSCLC. Berry et al. [8] reported that even a minor GGO component within NSCLC is associated with improved prognosis in clinical stage I-II tumors when compared to purely solid tumors. Furthermore, Yoon et al. [9] further demonstrated that in stage IA NSCLC lesions, a consolidation-to-tumor ratio exceeding 75% is a significant factor associated with poor prognosis. These findings suggest that the presence of GGO component may serve as a supplementary prognostic indicator for patients with the same T stage. 18F- FDG PET/CT plays an important role in the diagnosis, therapeutic response prediction and evaluation of NSCLC [11]. Previous studies have shown that preoperative PET metabolic parameters, including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total glycolysis (TLG), are prognostic factors for recurrence and survival in patients with stage IA NSCLC [12–15]. Furthermore, compared with SUVmax, which reflects the highest uptake value of a single voxel, the volumetric parameters MTV and TLG are considered to be more reliable prognostic biomarkers because they can reflect the overall tumor metabolic burden [15]. In a meta-analysis, Hyung et al. [16] examined a total of 1,581 NSCLC patients across 13 studies, and results revealed that MTV and TLG of primary tumor are significant prognostic factors in patients with stage I surgical NSCLC. Specifically, patients with higher MTV or TLG values are at a significantly elevated risk of adverse events and mortality. Although both GGO features and PET parameters have shown good predictive value for early-stage NSCLC, their combined use has not been reported. We hypothesize that integrating these two modalities can further refine prognostic stratification. Thus, this study aimed to develop and validate a simple and practical two-point prognostic scoring system by integrating anatomical and metabolic information derived from PET/CT imaging, to enhance prognostic risk stratification for patients with stage IA NSCLC and provide a valuable imaging tool for clinical. Materials and methods Patients We retrospectively reviewed consecutive patients with pathological stage IA NSCLC who underwent preoperative 18F-FDG PET/CT and curative resection at the First Affiliated Hospital of Jinan University between November 2012 and October 2024. All patients had been retrospectively staged again with the American Joint Committee on Cancer (AJCC) 9th edition for consistency [17]. Patients with negative surgical margins and who had complete follow-up information were eligible for the study. Those with other prior malignancies or who had received neoadjuvant chemotherapy or radiotherapy before surgery were excluded. This cohort served as the feasibility cohort for the prognostic scoring system. Furthermore, an external validation cohort, selected using the same inclusion and exclusion criteria, was retrospectively assembled from Jiangmen Central Hospital between February 2017 and October 2024. Demographic and clinicopathological data of patients at diagnosis were recorded, including age, sex, smoking status, histology, and tumor stage. Patients were scheduled for followed up every 6 months for the first 2 years and annually thereafter, with adjustments made to the interval based on their clinical status. Follow-up evaluations included medical history review, physical examination, abdominal ultrasound, thoracic CT, and additional diagnostic tests as clinically indicated. Follow-up data were obtained via medical record review and telephone interviews. This study was conducted in compliance with the principles of the Declaration of Helsinki. The institutional review boards of both participating hospitals approved the study protocol and granted a waiver for informed consent. PET/CT acquisition and imaging analysis 18F-FDG PET/CT scans were performed using either a GE Discovery PET/CT 690 scanner or a GE Discovery VCT 64 scanner at two clinical PET/CT centers. Prior to imaging, patients were required to fast for at least 6 h, with serum glucose levels confirmed to be < 200 mg/dL. PET/CT imaging was performed 50–70 min following intravenous administration of 18F-FDG (0.08–0.10 mCi/kg). The PET images were reconstructed using an iterative algorithm with CT-based attenuation correction. The imaging data were reviewed by two experienced nuclear medicine physicians from each center (four physicians in total), each with over eight years of clinical experience in PET/CT diagnosis. Any disagreements were resolved by consensus. The solid portion within the tumor was defined as the area of increased opacity obscuring vascular markings. GGO was defined as an area of hazy density without obscuring vascular structures [7]. Furthermore, the PET parameters of the tumors were analyzed using PET volume computer-assisted reading (PET VCAR), an automated segmentation system on the GE Advantage Workstation, which can find a threshold value that separates the target volume from the background tissue by using an iterative adaptive segmentation algorithm [18]. By drawing a volume of interest (VOI), the SUVmax, MTV, and TLG of the primary tumor were measured automatically. Statistical analysis The primary endpoint for survival analysis was progression-free survival (PFS), which was calculated from the date of surgery to the date of first recurrence, or death, or until the last known event-free date. Overall survival (OS), the interval from the date of surgery to death from any cause or final follow-up, was recorded as the secondary endpoint. Patient characteristics were compared between the two cohorts using the chi-square test of independence for categorical variables and the Mann-Whitney U-test for continuous variables, as appropriate. In the first step, the analysis was performed exclusively on the feasibility cohort. Patients were categorized as GGO-positive or GGO-negative group based on CT scans. For PET parameters, the optimal cut-off values for recurrence prediction were determined using receiver operating characteristic (ROC) curve analysis, with patients subsequently divided into two subgroups based on these values. The Kaplan-Meier method was used to estimate the PFS curves of the different subgroups, and the log-rank test was used to compare them. Univariate and multivariate Cox regression analyses were performed to identify the significant PET parameters associated with PFS. Then, a two-point prognostic scoring system was established based on GGO features and the independent prognostic PET parameter identified by multivariable analysis. Each variable was scored as 1 if present and 0 if absent. In the second step, the prognostic scoring system was employed to perform internal validation for the feasibility cohort and external validation for the validation cohort. Patients were divided into three risk groups based on scores: low-risk (score = 0), moderate-risk (score = 1), and high-risk (score = 2). The log-rank test was then applied to compare the three groups and evaluate the prognostic scoring system’s ability to stratify recurrence risk. All data were analyzed using SPSS software version 16, in which a P value of less than 0.05 was considered statistically significant. Results Characteristics of the feasibility and validation cohorts Table 1 summarizes the patient characteristics of both the feasibility and validation cohorts. The feasibility cohort comprised 152 patients (72 men and 80 women; mean age, 63.5 years; range, 35–79 years), of whom 58 (38.2%) were classified as GGO-positive and 94 (61.8%) as GGO-negative. The tumor stages were IA1 in 19 (12.5%) patients, IA2 in 66 (43.4%), and IA3 in 67 (44.1%) patients. The median follow-up duration was 29.2 months, during which 18 patients (11.8%) experienced recurrence, 18 (11.8%) died, and 134 (88.2%) remained alive at the time of analysis. The external validation cohort consisted of 60 patients (20 men and 40 women; mean age, 61.6 years; range, 29–84 years), with 28 (46.7%) GGO-positive and 32 (53.3%) GGO-negative cases. The tumor stages were IA1 in 17 (28.3%) patients, IA2 in 24 (40.0%), and IA3 in 19 (1.7%) patients. The median follow-up was 34.9 months, with 8 patients (13.3%) experienced recurrence, 2 (3.3%) died, and 58 (96.7%) alive at the final follow-up. A flow diagram of the study is shown in Fig. 1. All enrolled patients underwent curative-intent surgery accompanied by systematic lymph node dissection. A total of 42 patients received adjuvant chemotherapy or target-therapy after radical resection. The chemotherapy protocols involved carboplatin- or cisplatin-based combinations paired with agents such as paclitaxel, docetaxel, pemetrexed, or gemcitabine. The targeted therapies included icotinib or osimertinib. Analysis showed that adjuvant therapy did not significantly affect patient prognosis (all P > 0.05) (Fig. S1). Table 1Clinical characteristics of enrolled patientsPatient characteristicsfeasibility cohort (n = 152)Validation cohort (n = 60) P Age (mean ± SD) (years)63.5 ± 28.361.6 ± 10.70.137aGender n (%)0.063b Male72 (47.4%)20 (33.3%) Female80 (52.6%)40 (66.7%)Smoking history n (%)0.481b Never112 (73.7%)47 (78.3%) Ever/current40 (26.3%)13 (21.7%)Histology n (%)0.901b Adenocarcinoma128 (84.2%)49 (81.7%) Squamous cell carcinoma22 (14.5%)10 (16.7%) Large cell carcinoma2 (1.3%)1 (1.7%)TNM stage n (%)0.017b IA119 (12.5%)17 (28.3%) IA266 (43.4%)24 (40.0%) IA367 (44.1%)19 (31.7%)Type of surgery n (%)0.517b Lobectomy118 (77.6%)49 (81.7%) Wedge resection34 (22.4%)11 (18.3%)Adjuvant therapy n (%)0.269b No119 (78.3%)51 (85.0%) Chemotherapy/target therapy33 (21.7%)9 (15.0%)a Mann-Whitney U-test; b Chi-squared-test; SD, standard deviation Table 1Clinical characteristics of enrolled patientsPatient characteristicsfeasibility cohort (n = 152)Validation cohort (n = 60) P Age (mean ± SD) (years)63.5 ± 28.361.6 ± 10.70.137aGender n (%)0.063b Male72 (47.4%)20 (33.3%) Female80 (52.6%)40 (66.7%)Smoking history n (%)0.481b Never112 (73.7%)47 (78.3%) Ever/current40 (26.3%)13 (21.7%)Histology n (%)0.901b Adenocarcinoma128 (84.2%)49 (81.7%) Squamous cell carcinoma22 (14.5%)10 (16.7%) Large cell carcinoma2 (1.3%)1 (1.7%)TNM stage n (%)0.017b IA119 (12.5%)17 (28.3%) IA266 (43.4%)24 (40.0%) IA367 (44.1%)19 (31.7%)Type of surgery n (%)0.517b Lobectomy118 (77.6%)49 (81.7%) Wedge resection34 (22.4%)11 (18.3%)Adjuvant therapy n (%)0.269b No119 (78.3%)51 (85.0%) Chemotherapy/target therapy33 (21.7%)9 (15.0%)a Mann-Whitney U-test; b Chi-squared-test; SD, standard deviation Clinical characteristics of enrolled patients a Mann-Whitney U-test; b Chi-squared-test; SD, standard deviation Fig. 1The flowchart of patient inclusion and exclusion. NSCLC, non-small cell lung cancer; 18F-FDG PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography The flowchart of patient inclusion and exclusion. NSCLC, non-small cell lung cancer; 18F-FDG PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography Prognostic value of PET parameters and GGO features in the feasibility cohort Table 2 presents the mean values and optimal cut-off points of various PET parameters as determined by ROC curve analysis in the feasibility cohort. Significantly higher values of SUVmax, MTV, and TLG were observed in the recurrence group compared to the non-recurrence group (all P < 0.05). ROC-derived optimal cut-off values were 6.2 for SUVmax, 1.9 mL for MTV, and 11.7 for TLG. Patients exhibiting PET parameters above these thresholds at the primary tumor site demonstrated significantly shorter PFS (all P < 0.05). Additionally, Patients in the GGO-negative group also had significantly worse PFS than those in the GGO-positive group (P < 0.05). The Kaplan-Meier survival analyses, stratified by GGO features and dichotomized values of SUVmax, MTV, and TLG, are presented in Fig. 2. Furthermore, patients who were GGO-negative or had elevated PET parameters showed significantly worse OS compared to their corresponding control groups (all P < 0.05) (Fig. S2). Table 2The description of mean values and the optimal cutoff values of PET parametersParameterTotal(mean ± SD)Recurrence(mean ± SD)No recurrence(mean ± SD) P a CutoffAUC (95% CI)SUVmax4.89 ± 3.678.33 ± 4.244.21 ± 3.15< 0.0016.20.800 (0.715–0.884)MTV (mL)4.33 ± 6.897.47 ± 14.693.72 ± 3.630.0211.90.668 (0.576–0.761)TLG13.72 ± 22.8529.08 ± 43.9910.69 ± 14.11< 0.00111.70.787 (0.700-0.873)a Mann-Whitney U test. PET, positron emission tomography; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; SD, standard deviation; AUC, area under the curve; CI, confidence interval Table 2The description of mean values and the optimal cutoff values of PET parametersParameterTotal(mean ± SD)Recurrence(mean ± SD)No recurrence(mean ± SD) P a CutoffAUC (95% CI)SUVmax4.89 ± 3.678.33 ± 4.244.21 ± 3.15< 0.0016.20.800 (0.715–0.884)MTV (mL)4.33 ± 6.897.47 ± 14.693.72 ± 3.630.0211.90.668 (0.576–0.761)TLG13.72 ± 22.8529.08 ± 43.9910.69 ± 14.11< 0.00111.70.787 (0.700-0.873)a Mann-Whitney U test. PET, positron emission tomography; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; SD, standard deviation; AUC, area under the curve; CI, confidence interval The description of mean values and the optimal cutoff values of PET parameters a Mann-Whitney U test. PET, positron emission tomography; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; SD, standard deviation; AUC, area under the curve; CI, confidence interval Fig. 2Progression-free survival stratified by (A) GGO features, (B) SUVmax, (C) MTV, and (D) TLG in stage IA NSCLC patients from the feasibility cohort. GGO, ground-glass opacity; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis Progression-free survival stratified by (A) GGO features, (B) SUVmax, (C) MTV, and (D) TLG in stage IA NSCLC patients from the feasibility cohort. GGO, ground-glass opacity; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis Risk factors of PFS in the feasibility cohort Table 3 summarizes the results of the univariate and multivariate analyses. In univariate analysis, non-adenocarcinoma histology, containing GGO component, SUVmax >6.2, MTV > 1.9 mL, and TLG > 11.7 were significantly associated with an increased risk of recurrence (all P < 0.05). Multivariate analysis revealed that GGO features [hazard ratio (HR) = 8.137; 95% CI: 1.035–63.998; P = 0.046] and TLG (HR = 4.993; 95% CI: 1.831–13.612; P = 0.002) were independent risk factors for PFS, even after adjusting for histology and other PET parameters. Based on these findings, a two-point prognostic scoring system was developed. One point was assigned for either pure-solid nodule (GGO-negative) or TLG > 11.7; otherwise, 0 points were given. This scoring system effectively stratifies stage IA NSCLC into three distinct prognostic groups. The prognostic scores and corresponding pathological subtype distributions for patients in the feasibility and validation cohorts ​are presented​ in Table 4. Table 3The risk factors for recurrence in patients with stage IA NSCLCHR95% P HR95% P Age (≤ 60 vs. >60 years)1.1810.498–2.8010.705Sex (female vs. male)0.6840.320–1.4610.326Smoking (never vs. ever/current)1.8860.875–4.0670.105Surgical approaches (lobectomy vs. wedge)1.6960.739–3.8920.212Adjuvant therapy (no vs. yes)1.4790.658–3.3250.344Histology (adenocarcinoma vs. non adenocarcinoma)2.4121.079–5.3920.032TNM stage (IA1-2 vs. IA3)0.9890.465–2.1270.989GGO (GGO-positive vs. GGO-negative)17.9702.447-133.2460.0058.1371.035–63.9980.046SUVmax (≤ 6.2 vs. >6.2)5.3852.416–12.002< 0.001MTV (≤ 6.2 vs. >6.2)14.7642.003-108.8520.008TLG (≤ 11.7 vs. >11.7)8.8313.342–23.334< 0.0014.9931.831–13.6120.002GGO, ground-glass opacity; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis Table 3The risk factors for recurrence in patients with stage IA NSCLCHR95% P HR95% P Age (≤ 60 vs. >60 years)1.1810.498–2.8010.705Sex (female vs. male)0.6840.320–1.4610.326Smoking (never vs. ever/current)1.8860.875–4.0670.105Surgical approaches (lobectomy vs. wedge)1.6960.739–3.8920.212Adjuvant therapy (no vs. yes)1.4790.658–3.3250.344Histology (adenocarcinoma vs. non adenocarcinoma)2.4121.079–5.3920.032TNM stage (IA1-2 vs. IA3)0.9890.465–2.1270.989GGO (GGO-positive vs. GGO-negative)17.9702.447-133.2460.0058.1371.035–63.9980.046SUVmax (≤ 6.2 vs. >6.2)5.3852.416–12.002< 0.001MTV (≤ 6.2 vs. >6.2)14.7642.003-108.8520.008TLG (≤ 11.7 vs. >11.7)8.8313.342–23.334< 0.0014.9931.831–13.6120.002GGO, ground-glass opacity; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis The risk factors for recurrence in patients with stage IA NSCLC GGO, ground-glass opacity; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis Table 4Prognostic scores and associated pathological subtype distributionsScoreFeasibility cohortsValidation cohortsAdenocarcinoma (%)Non adenocarcinoma (%)TotalAdenocarcinoma (%)Non adenocarcinoma (%)Total047 (90.4%)5 (9.6%)5227 (100%)0 (0%)27148 (92.3%)4 (7.7%)5212 (75.0%)4 (25.0%)16232 (66.7%)16 (33.3%)4810 (58.8%)7 (41.2%)17 Table 4Prognostic scores and associated pathological subtype distributionsScoreFeasibility cohortsValidation cohortsAdenocarcinoma (%)Non adenocarcinoma (%)TotalAdenocarcinoma (%)Non adenocarcinoma (%)Total047 (90.4%)5 (9.6%)5227 (100%)0 (0%)27148 (92.3%)4 (7.7%)5212 (75.0%)4 (25.0%)16232 (66.7%)16 (33.3%)4810 (58.8%)7 (41.2%)17 Prognostic scores and associated pathological subtype distributions Performance of the scoring prognostic system in the risk stratification of patients The two sets of patients were classified into high-, moderate- and low-risk groups according to the two-point prognostic scoring system. Patients from the feasibility cohort served as the internal validation, with results indicating that those with low-risk showed significantly longer PFS than moderate-risk groups (P = 0.012), while moderate-risk patients also had significantly better PFS than high-risk patients (P = 0.001) (Fig. 3A). More importantly, when applied to each specific stage, significantly different PFS of three different groups in stages IA2, and high- and low-risk groups in stages IA3 (all P < 0.05) (Fig. 3B and C), and a clear trend of higher score being associated with worse PFS for all three substages. This was supported by the results of the external validation cohort, where significant PFS differences were observed between low- and high-risk groups, and moderate- and high-risk groups (all P < 0.05) (Fig. 3D). Fig. 3Progression-free survival stratified by the two-point prognostic scoring system in stage IA NSCLC patients: (A) overall stage IA, (B) IA2, and (C) IA3 subgroups from the feasibility cohort, and (D) stage IA from the external validation cohort. NSCLC, non-small cell lung cancer Progression-free survival stratified by the two-point prognostic scoring system in stage IA NSCLC patients: (A) overall stage IA, (B) IA2, and (C) IA3 subgroups from the feasibility cohort, and (D) stage IA from the external validation cohort. NSCLC, non-small cell lung cancer Furthermore, a significant difference in OS was observed among patients with different risk scores in the feasibility cohort (all P < 0.05) (Fig. S3). However, due to only two deaths occurred during follow-up in the external validation cohort, the predictive value of the scoring system for OS in this group was not assessed. These results indicate that the two-point prognostic scoring system can be applied to predict the prognosis of patients with stage IA NSCLC. The representative clinical cases are shown in Fig. 4. Fig. 4Representative clinical cases and related PET/CT images. (A) A 66-year-old female patient with a 2.6 cm GGO tumor in the right lung apex exhibited minimal FDG uptake (score 0) and remained recurrence-free during 93 months postoperative follow-up. (B) A 55-year-old female patient with a 2.3 cm pure-solid tumor in the right middle lobe lateral segment showing mild FDG uptake (score 1) and had no recurrence during 74 months of follow-up. (C) A 65-year-old male patient with a 2.1 cm pure-solid tumor in the left upper lobe showing intense FDG uptake (score 2) and developed pulmonary recurrence at 15 months postoperative follow-up. GGO, ground-glass opacity; FDG, fluorodeoxyglucose Representative clinical cases and related PET/CT images. (A) A 66-year-old female patient with a 2.6 cm GGO tumor in the right lung apex exhibited minimal FDG uptake (score 0) and remained recurrence-free during 93 months postoperative follow-up. (B) A 55-year-old female patient with a 2.3 cm pure-solid tumor in the right middle lobe lateral segment showing mild FDG uptake (score 1) and had no recurrence during 74 months of follow-up. (C) A 65-year-old male patient with a 2.1 cm pure-solid tumor in the left upper lobe showing intense FDG uptake (score 2) and developed pulmonary recurrence at 15 months postoperative follow-up. GGO, ground-glass opacity; FDG, fluorodeoxyglucose Discussion In the present study, we constructed a two-point prognostic scoring system incorporating both tumor anatomical and metabolic features to predict PFS in stage IA NSCLC patients undergoing radical surgery. The results demonstrated that patients with pure-solid tumor (GGO-negative) and high SUVmax, MTV, or TLG had significantly shorter PFS. Importantly, the prognostic scoring system—integrating GGO features and TLG, both of which remained independent predictors of recurrence in multivariate analysis—showed consistent and robust risk stratification capability across internal and external validation datasets. This clinically applicable scoring system will effectively optimize the early treatment strategies, provide personalized care and interventions, and improve prognosis through precise and individualized management. Previous studies have demonstrated that 8.8% to 29.8% of patients with stage IA NSCLC experience tumor recurrence following surgical resection, with the majority of recurrences occurring within the first three postoperative years [2–4]. Our research results are consistent with these observations. The overall recurrence rates were 11.8% in the feasibility cohort and 15.0% in the external validation cohort, with 66.7% and 62.5% of recurrences occurring within the first 3 postoperative years in each cohort, respectively. Additionally, we found significantly worse OS in patients with tumor recurrence than in those without, which is in line with earlier research [4]. The prognosis of resectable NSCLC primarily depends on TNM staging, but significant variability exists within the same stage due to histopathology, tumor biology, and patient-specific factors. Previous studies have found that the presence of a GGO component could represent an independent predictor of good prognosis, regardless of the subclassification of the T stage [7]. In contrast, radiologic pure-solid nodules have 11–24% occult lymph node metastasis rates despite surgery and are more aggressive with worse outcomes than GGO nodules [19, 20]. Similarly, we found that GGO-containing tumors were associated with significantly longer PFS, whereas the pure-solid subgroup exhibited worse outcomes. This phenomenon can be explained that the GGO component histologically corresponds to the lepidic growth pattern of adenocarcinoma and a higher proportion of lepidic components are associated with a lower risk of recurrence [21, 22]. Therefore, prognostic evaluation in stage IA NSCLC should first be classified based on whether the tumor contains a GGO component, and then further stratified according to the clinical high-risk factors. Previous studies have shown that volumetric PET parameters, MTV and TLG, provide a more accurate assessment of tumor burden and biological aggressiveness compared to SUVmax [16]. MTV reflects the volume of metabolically active tumor tissue, while TLG incorporates both tumor volume and metabolic activity. In a study of 299 surgically treated stage I NSCLC patients, Hyun et al. [14] demonstrated that preoperative MTV and TLG independently predicted recurrence and mortality, irrespective of histology, tumor stage, or surgical approach, whereas SUVmax lacked prognostic significance. Similarly, Seong Yong Park et al. [15] analyzed 248 stage IA patients and found that TLG was the only metabolic parameter significantly associated with overall survival. Consistent with previous findings, univariate analysis in the present study revealed significant associations between primary tumor SUVmax, MTV, and TLG and recurrence risk. However, only TLG retained independent prognostic significance in multivariate analysis. Histologic subtype is a well-established prognostic factor in NSCLC [23, 24]. In this study, univariate analysis also showed significantly worse prognosis in non-adenocarcinoma compared to adenocarcinoma patients. Notably, high-risk scored patients exhibited a higher proportion of non-adenocarcinoma histology, suggesting that greater biological aggressiveness may radiologically present as larger tumors and elevated metabolic characteristics [25, 26]. Consequently, histology lost independent prognostic value on multivariate analysis, as GGO feature and TLG reflect tumor aggressiveness that overlaps with histology-driven prognosis. Furthermore, although a subset of patients received adjuvant therapy, no association was observed with PFS (P >0.05). This is consistent with current evidence that adjuvant therapy provides limited survival benefit in stage IA NSCLC [27]. The combined evaluation of GGO features and TLG demonstrated significant added prognostic value in both internal and external validation cohorts. The two-point prognostic scoring system effectively stratified patients into three risk groups with different PFS. In addition, in the analysis of the IA2 and IA3 subgroups from the feasibility cohort, the scoring system consistently maintained strong prognostic discrimination. Furthermore, ​despite​ differences in stage distribution between the external validation and feasibility cohorts, the scoring system maintained ​robust stratification accuracy​ across both cohorts. This stratification could provide actionable clinical guidance, patients scoring 0 points showed negligible recurrence rates, supporting conservative follow-up strategies, while those scoring 2 points may benefit from intensified therapeutic intervention. The advantage of this method is simplicity and practicality. Unlike radiomics models, which use complex algorithms and features to predict outcomes in stage IA NSCLC patients [12, 28], this system only needs two easy-to-use imaging parameters, making it easier to use in clinical practice. Additionally, this two-point approach avoids the limitations of using just one parameter. However, it should be noted that SUVmax values can be affected by various factors, and the optimal segmentation method for calculating MTV and TLG remains a topic of debate [29]. Therefore, we suggest that institutions establish their optimal PET parameter thresholds and implement the standardized quality control and assurance procedures recommended by the European Association of Nuclear Medicine (EANM), together with uniform image acquisition and processing protocols across all centers, to improve measurement accuracy, precision, and multicenter reproducibility [30]. Furthermore, the EANM Research Limited (EARL) harmonization strategy or commercial software like EQ.PET can further ensure harmonized quantitative measurements across institutions [31]. The current study has some limitations. First, its retrospective design and relatively small sample size may introduce inherent biases. For example, multiple comparisons with a limited number of events increase the risk of false-positive findings, although multivariate analysis and external validation mitigated this concern. Second, we did not include key molecular markers such as epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) rearrangement, and programmed death-ligand 1 (PD-L1) expression, which are established prognostic factors in NSCLC [32]. These markers can also guide adjuvant treatment planning; for example, EGFR-activating mutations predict response to gefitinib and erlotinib [33]. The absence of these elements limits the scoring system’s effectiveness in guiding personalized adjuvant therapy. Third, while surgical approach and adjuvant chemotherapy did not demonstrate prognostic significance in our analysis, variations in surgical techniques and individualized treatments may have contributed to minor heterogeneity in patient management. Therefore, future prospective studies with larger, homogeneous cohorts, extended follow-up periods, and comprehensive clinicopathological and molecular biomarker data are needed to validate our findings. In conclusions, GGO component and PET metabolic parameters, especially TLG, were significantly associated with recurrence risk in patients with stage IA NSCLC. The two-point prognostic scoring system that integrates GGO and TLG provides a simple but effective approach for improved prognostic stratification of stage IA NSCLC following surgical resection. This may help to identify patients who could benefit from post-operative adjuvant therapy. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1